{
    "url_original": "https://www.wsj.com/articles/blackstone-to-invest-up-to-250-million-in-autolus-therapeutics-of-u-k-11636336822?mod=markets_lead_pos2",
    "url": "blackstone-to-invest-up-to-250-million-in-autolus-therapeutics-of-u-k-11636336822",
    "title": "Blackstone to Invest Up to $250 Million in Autolus Therapeutics of U.K.",
    "sub_head": "Funds will help develop a leukemia therapy; under deal, the private-equity firm intends to buy a $100 million stake in the biotech company",
    "category_1": "Deals",
    "image_1_url": "https://images.wsj.net/im-430720?width=860&height=573",
    "image_1": "im-430720.jpg",
    "time": "2021-11-07 21:00:00",
    "body": "Blackstone Inc.  is investing as much as $250 million in U.K. biotechnology company  Autolus Therapeutics  PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.<br />Of the total investment, as much as $150 million will support the development and commercialization of obecabtagene autoleucel, a cell therapy that targets a condition called acute lymphoblastic leukemia. London-based Autolus will receive $50 million of that upfront, with the rest to be paid as the company achieves certain milestones. In return, Blackstone’s life-sciences unit will receive a portion of the therapy’s royalties."
}